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Introduction
Cells are naturally endowed with mechanisms that induce
apoptosis, a characteristic that underlies the successful
use of standard cancer drugs and radiation. The growth of
a tumor, however, is exquisitely dependent upon overcom-
ing the normal tendency of a cell to die under stress con-
ditions. A major clinical problem is thus the ability of
malignant cells to evade cancer drugs, either by altering
expression of surveillance molecules or by upregulating
signaling pathways capable of promoting cell survival and
proliferation, even in the presence of an apoptosis-induc-
ing agent.
A recent paper from the laboratory of Charles Streuli
described the ability of ZD1839, a small-molecule inhibitor
of the epidermal growth factor receptor (EGFR), to induce
apoptosis of normal mammary cells [1]. In this system,
insulin-like growth factor-1 (IGF-1) and epidermal growth
factor (EGF) are two important survival factors. Interest-
ingly, ZD1839 was effective in inducing cell death not only
in the presence of EGF, but also in the presence of IGF-1.
Furthermore, the authors shed light on the mechanisms
underlying ZD1839-mediated apoptosis, showing that
BAD, a BCL-2 family member, is an important survival
target of the EGFR in mammary cells. The results are
promising, considering the importance of this receptor in
breast cancer development. In the future, it will be essen-
tial to understand the mechanisms by which apoptosis
can be triggered in tumors in order to achieve the desired
efficacy in cancer therapeutics.
Receptor tyrosine kinases and cancer
Members of the ErbB family of receptor tyrosine kinases
play important roles in normal biology of the breast and in
cancer. Upon ligand binding to the extracellular domain,
these receptors form homodimers and heterodimers
leading to activation of the intracellular kinase domain and
phosphorylation on specific tyrosine residues. These
tyrosines then serve as docking sites for molecules that
further transduce the signal, leading to activation of the
mitogen-activated protein kinase (MAPK) pathway and the
phosphoinositide-3 kinase (PI3K)/protein kinase B
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pathway, among others [2]. Alterations in expression and
activation of the EGFR and ErbB2 are relatively common
in breast cancer. Furthermore, these receptors have also
been implicated in the development of many other types of
solid tumors [3,4].
The IGF-1 receptor (IGF-1R), like the insulin receptor, is
composed of α and β chains, and ligand binding induces
the formation of a heterotetrameric complex. The activated
IGF-1R phosphorylates a major substrate, IRS1, on multi-
ple sites, forming a signaling platform that stimulates mito-
genic and survival pathways, including MAPK and PI3K
[5]. IGF-1 expression is a prognostic factor for increased
risk of developing breast cancer [6]. Moreover, over-
expression of the IGF-1R and elevated serum IGF-1 levels
have been observed in breast cancer patients [6].
Because of their evident role in cancer, the receptor
tyrosine kinases (in particular, ErbB receptors) have been
vigorously pursued as promising targets. Specific mAbs
were among the earliest described therapeutics; these
include C225 (EGFR specific) and Herceptin (ErbB2
specific) [4]. Small molecular weight ErbB kinase inhibitors
are also in various stages of clinical development [3,4].
ZD1839 (Iressa), an anilinoquinazoline that blocks EGFR
activity, was used in the studies of Gilmore et al. [1].
ZD1839 causes apoptosis of normal
mammary cells
Apoptosis, a highly regulated process, is triggered by
different mechanisms. They are broadly classified as ‘extrin-
sic’ when occurring via activation of a death receptor, or
‘intrinsic’ when the mitochondria and members of the BCL-
2 family take part [7]. This large protein family is comprised
of anti-apoptotic and pro-apoptotic molecules whose
members share up to four BCL-2 homology (BH) domains.
Very generally, the members can be divided into three sub-
classes: those like the multidomain BCL-2 and BCL-XL,
which are anti-apoptotic; those like the multidomain BAX
and BAK, which are pro-apoptotic; and, finally, the BH3
domain-only pro-apoptotic proteins, such as BID, BIK and
BAD. The latter group uses the BH3 domain to interact with
the multidomain BCL-2 family members, and can be further
divided based upon preferred binding partners. Recent
results [8] suggest that the BH3 domain-only proteins func-
tion to induce apoptosis by two mechanisms: the BID-like
BH3 domains activate the pro-apoptotic BAX and BAK; and
the BAD-like BH3 domains bind anti-apoptotic BCL-2 or
BCL-XL, thus interfering with their activity. The activity of the
BH3 domain-only proteins is controlled by various mecha-
nisms ranging from transcriptional to protein modification.
BAD, the protagonist of Gilmore et al.’s publication, is reg-
ulated by phosphorylation. Growth factors and cytokines
stimulate BAD phosphorylation on specific serine
residues: S112, S136, S155 and S170. Depending upon
the cell type and the inducing agent, various kinases phos-
phorylate BAD, including p90Rsk-1, protein kinase A,
protein kinase B and p70S6 kinase [9–14]. Phosphoryla-
tion of BAD on these residues promotes its binding to,
and subsequent cytosolic sequestration by, 14-3-3 pro-
teins [15]. Importantly, these modifications prevent BAD
from associating with BCL-2 or BCL-xL on the mitochondr-
ial outer membrane, leaving these proteins free to exert
their anti-apoptotic function [15].
The EGFR and the IGF-1R have survival and proliferative
roles in normal mammary cells; in serum-free conditions,
primary mammary cells must be grown in EGF or IGF-1 to
prevent apoptosis. The results of Gilmore et al. show that
BAD is the target of signaling pathways emanating from
both receptors [1]. EGF induces phosphorylation of S112
via MAPK activation; and IGF-1 induces both S112 and
S136 phosphorylation, the latter via the PI3K pathway.
ZD1839 blocks the EGFR and the downstream MAPK
activity, leading to a decrease in S112 phosphorylation
and induction of apoptosis. Intriguingly, IGF-1-mediated
survival of primary mammary cells is also blocked by
ZD1839. These results suggest that IGF-1R transactiva-
tion of the EGFR, which occurs in the mammary cell line,
is the main mechanism by which IGF-1 maintains survival
of primary mammary cells.
What influences BAD activity in breast cells?
Considering the importance of BAD inactivation in promot-
ing survival of normal mammary cells, as shown by Gilmore
et al. [1], it is interesting to consider factors that might influ-
ence BAD’s activity, particularly in cancer cells. BAD is
widely expressed [16] and its level might play an important
role in treatment outcome. For example, loss of or decrease
in BAD expression during the course of tumor development
might allow the prosurvival proteins BCL-2 or BCL-xL to
function unopposed to this potent inhibitor. In fact, in
normal human breast cells, BAD levels are relatively high in
comparison with those in other organs [16], suggesting
that BAD might have a special role in the breast. Indeed,
Gilmore et al. [1] showed that transient BAD overexpres-
sion enhances the sensitivity of mammary cells to apopto-
sis, perhaps because the S112 and S136 kinases become
limiting. On the other hand, primary cultures of BAD–/–
mammary cells are no longer sensitive to ZD1839-induced
apoptosis, suggesting that BAD might be the important
pro-apoptotic effector downstream of the EGFR.
Tumor cells might also develop mechanisms to circumvent
BAD-induced apoptosis. While primary mammary cells
appear to use mainly MAPK for survival, both in response
to EGF as well as to IGF-1 [1], tumor cells might use
multiple survival pathways that could impinge on BAD. In
fact, in the presence of IGF-1, the FSK mammary cells are
not as sensitive to ZD1839-induced apoptosis as the
primary mammary cells. Their results show that these cells29
rely on both the MAPK and the PI3K pathway for survival, a
mechanism that is likely to be quite common in tumor cells.
Can receptor tyrosine kinase inhibitors
trigger apoptosis in malignant breast cells?
The results of Gilmore et al. [1] show that normal
mammary cells are exquisitely dependent upon survival
signals emanating from the EGFR. Can these findings be
put to use for breast cancer therapy? In other words, are
breast tumor cells equally dependent upon these path-
ways for their survival?
It has been well documented that agents targeting
members of the EGFR family generally yield satisfactory
growth inhibitory results [3,4,17,18]. Apoptosis, however,
appears to be triggered mainly when a combined therapy
is employed. Turning to in vivo tumor models, a humanized
EGFR antibody (ABX-EGF) appears to cause tumor cell
death [19]. Furthermore, EGFR inhibitors have been
shown to have growth inhibitory effects on ErbB receptor-
driven orthotopic tumor models [20,21] and, in the latter,
to induce apoptosis, although the effectors have not yet
been identified.
Returning to the results of Gilmore et al. [1], they showed
that metastatic breast cancer cells, isolated from one
patient who had failed multiple therapies, underwent
apoptosis in the presence of ZD1839. This suggests that
EGFR kinase inhibitors can potentially cause apoptosis of
malignant breast cells, and highlights the potential efficacy
of such therapy in this tissue.
Future goals
The success of future therapies depends on their ability to
interfere with distinct pathways leading to apoptosis. Con-
sidering BAD’s facility to function as a switch between life
and death, and its regulation via both phosphorylation and
localization, the development of inhibitors of multiple sig-
naling proteins, as well as of molecules that interfere with
protein–protein interactions, would be valuable. In this
regard, it has been reported that synthetic peptides that
mimic the BH3 domain of the pro-apoptotic family
members BAX and BAK were able to induce apoptosis
[22,23]. In addition, small molecules that inhibit the
binding of BAK to BCL-xL, by specifically blocking the
BH3-mediated interaction with the survival molecule,
resulted in cell death both in vitro and in vivo.
Finally, the interaction between BAD and 14-3-3 proteins
might itself be a target for intervention. Intriguingly, a recent
report shows that, in postmitotic neurons, Cdc2-mediated
phosphorylation of BAD on S128 inhibits the interaction of
phospho-S136 with 14-3-3, leading to apoptosis [24]. It
might thus be possible to develop small molecules that
directly block the ability of phospho-BAD to interact with
14-3-3, thereby freeing its pro-apoptotic function.
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